

Pieza de resección neoplásica con Rabdomiosarcoma:

Informe basado en protocolo CAP vigente, AJCC/UICC TNM, 8ª ed.:

- Tratamiento previo: no procede. / quimioterapia (especificar). / radioterapia. / otros (indicar).
- Procedimiento: resección marginal. / resección local amplia. / resección radical. / amputación.
- Localización tumoral: ductos biliares. / vejiga. / próstata. / cráneo. / parameningea. / extremidades. / genitourinario. / cabeza y cuello. / órbita.
- Tamaño tumoral:
 - * Dimensión mayor: cm.
 - * Otras dimensiones: cm.
- Tipo histológico: rabdomiosarcoma embrionario. / alveolar. / fusiforme-esclerosante. / ectomesenquimoma. / NOS.
- Anaplasia: no identificado. / focal (focales-ocasionales células anaplásicas). / difusa (grupos o nidos de células anaplásicas).
- Efecto del tratamiento neoadyuvante: no se observa. / % tumor viable.
- Márgenes quirúrgicos:
 - * Margen proximal: libre, a mm de margen teñido.
 - * Margen distal: libre, a mm de margen teñido.
 - * Margen radial: libre, a mm de margen teñido.
- Ganglios linfáticos regionales:
 - * Número de ganglios aislados: .
 - * Número de ganglios metastatizados: /.
- Metástasis: no identificadas. / presente (especificar).
- Otros hallazgos:
 - *
- Fusión de estudios genéticos:
 - * Sin reordenamiento de FOXO1:
 - * Reordenamiento de FOXO1: sin "partner conocido". / FOXO1-PAX3. / FOXO1-PAX7.
 - * Otros (especificar).
- Estudios genéticos moleculares:
 - * Mutación DICER1
 - * Mutación MyoD1 L122R.
 - * Fusión de VGLL2 / NCOA2.
 - * Fusión EWSR1 / FUS-TFCP2.
- Método de estudio genéticos / moleculares:
 - * FISH
 - * Secuenciación (especificar).
 - * Microarray.

Clasificación tumoral:

The Intergroup Rhabdomyosarcoma Study Postsurgical Clinical Grouping System

Group IA Localized tumor, confined to site of origin, completely resected

Group IB Localized tumor, infiltrating beyond site of origin, completely resected

Group IIA Localized tumor, gross total resection, but with microscopic residual disease

Group IIB Locally extensive tumor (spread to regional lymph nodes), completely resected

Group IIC Locally extensive tumor (spread to regional lymph nodes), gross total resection, but microscopic residual disease

Group IIIA Localized or locally extensive tumor, gross residual disease after biopsy only

Group IIIB Localized or locally extensive tumor, gross residual disease after major resection (greater than 50% debulking)

Group IV Any size primary tumor, with or without regional lymph node involvement, with distant metastases, without respect to surgical approach to primary tumor.

Modified Site, Size, Metastasis Staging for Rhabdomyosarcoma (for relevant stage)

Stage I (requires all of the following to be true: Tumor involves favorable site (i.e., biliary tract / liver, orbit, head and neck [excluding parameningeal] or genitourinary site [excluding bladder / prostate]), and; Tumor metastatic to distant site not identified)

Stage II (requires all of the following to be true: Tumor involves unfavorable site (i.e., bladder / prostate, extremity, parameningeal or other site not mentioned in stage I), and; Tumor size less than or equal to 5 cm, and; Tumor involvement of lymph nodes not identified, and; Tumor metastatic to distant site not identified)

Stage III (requires that one of the following be true: Tumor involves unfavorable site, is less than or equal to 5 cm, and involves regional lymph nodes, but distant metastases are not identified, or; Tumor involves unfavorable site and is greater than 5 cm, with or without regional lymph node involvement, but distant metastases are not identified)

Stage III Findings

- Tumor involves unfavorable site, is less than or equal to 5 cm, and involves regional lymph nodes, but distant metastases are not identified*
- Tumor involves unfavorable site and is greater than 5 cm, with or without regional lymph node involvement, but distant metastases are not identified*
- Stage IV (requires that distant metastases be present)*